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ABSTRACT
The role of donor lymphocyte infusion (DLI) in themanagement of lymphoidmalignancies after allogeneic stem
cell transplantation (SCT) has not been clearly characterized. There is emerging evidence pointing to the effec-
tiveness of this approach, particularly in patients with low-grade disease, although to date this has been reported
only in small numbers of patients, and thus the utility of this treatment remains uncertain. A total of 28 patients
with low-grade lymphoid malignancies previously treated with allogeneic SCT received a total of 68 infusions of
donor lymphocytes. The diagnoses were indolent non-Hodgkin lymphoma (NHL; n 5 23) and transformed
NHL (n 5 5), and the indications for DLI were progressive disease with or without mixed chimerism (MC)
(n 5 17) and persistent MC alone (n 5 11). Escalating doses of cells were administered in the absence of graft-
versus-host disease (GVHD) or continued disease progression, until stable full donor chimerism or disease
response were achieved. The cumulative response rates after DLI to treat progressive disease and persistent
MC were 76.5% and 91.6%, respectively. The major toxicity resulting from the use of donor lymphocytes was
GVHD. The cumulative incidence of acute grade II-IV disease was 15%, and that of extensive chronic disease
was 31%; there were no deaths resulting from GVHD. Seven patients had graft-versus-lymphoma responses
without significant GVHD. These data support the existence of a clinically significant graft-versus-tumor effect
in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT.
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Allogeneic stem cell transplantation (SCT) is a
potentially curative therapy for patients with non-
Hodgkin lymphoma (NHL), although its role in the
treatment of this group of diseases remains unclear.
Several studies have demonstrated a long-term survival
advantage of allogeneic SCT over autologous SCT
[1,2]. Part of this benefit is derived from the use of
an uncontaminated graft, supported by the reduced re-
lapse rate observed after syngeneic transplantation
compared with autologous procedures [3]. A second
mechanism for this advantage is a graft-versus-tumor50(GVT) effect. The antitumor capacity of allogeneic
T lymphocytes in recipients of allogeneic SCT has
long been recognized [4], most notably in the treat-
ment of chronic myelogenous leukemia (CML) [5].
The evidence for a clinically significant GVT effect
in lymphoma is less robust, however. Comparison of
the outcome of syngeneic and allogeneic SCT for pa-
tients with NHL demonstrated similar relapse rates in
each group [3]. Furthermore, there is no clear associa-
tion between the development of GVHD and reduced
relapse rate [3,6]. These data have been interpreted as
demonstrating a lack of GVT effect in NHL [3],
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the relatively small numbers and heterogeneity of the
patients studied [6,7]. In contrast, the response to ei-
ther withdrawal of immunosuppression or DLI pro-
vides more direct evidence of a significant GVT
effect, although to date this has been demonstrated
only in case reports or small series [7-17].
The utility of allogeneic transplantation is limited
by the procedure related toxicity and with a median
age at diagnosis in the mid-60’s [18], most patients
with NHL are ineligible for this treatment. The devel-
opment of reduced-intensity transplantation (RIT) has
allowed application of allogeneic therapies to a broader
range of patients. Whereas RIT allows durable en-
graftment with reduced toxicity, GVHD remains a sig-
nificant cause of morbidity and mortality [19].
Incorporation of in vivo T cell depletion (TCD) into
conditioning protocols decreases the GVHD-associ-
ated morbidity and mortality [20-22], although it is as-
sociatedwith impaired immune reconstitution, leading
to an increased incidence of opportunistic infections,
and a decreased remission duration possibly resulting
from less GVT activity [12,23,24]. The increased re-
lapse risk after T-deplete RITmay be abrogated by ad-
ministering escalating doses of DLI [25], and although
emerging evidence indicates that this approach may be
effective in the treatment of lymphoproliferative dis-
eases, the current body of literature supporting this ap-
proach is small, with little consistency in the
indications, timing, or dose of DLI [7-17]. Here we
retrospectively report the results of administration of
dose-escalated DLI to 28 patients with indolent lym-
phoid malignancies after allogeneic SCT.
PATIENTS AND METHODS
Patients
A total of 81 consecutive patients underwent allo-
geneic SCT at a single institution between 1997 and
2004 for indolent lymphoid malignancies; 28 subse-
quently received DLI and are included in this retro-
spective study (Table 1). The indications for DLI
were disease progression or mixed chimerism (MC) 6
months from the date of transplantation, without sig-
nificant GVHD (acute grade III-IV or extensive
chronic disease [aGVHD, cGVHD]). Otherwise eligi-
ble candidates for DLI who were not treated for
GVHD were not included. A total of 26 patients re-
ceived RIT (fludarabine 150 mg/m2 in 5 divided doses,
melphalan 140 mg/m2, and alemtuzumab 100 mg in 5
divided doses in 22 patients and 60 mg in 2 divided
doses in 7 patients) and an unmanipulated peripheral
blood stem cell (PBSC) graft (n 5 24) or a bone mar-
row (BM) graft (n 5 2) from a sibling (n 5 22), a
matched unrelated donor (n 5 3), or a single antigen-
mismatched unrelated (n 5 1) donors, with cyclo-
sporine as GVHD prophylaxis [20]. The remaining 2patients received myeloablative conditioning with to-
tal body irradiation (TBI; 12 Gy in 6 fractions) and
cyclophosphamide (120 mg/kg in 2 divided doses),
an unmanipulated sibling BM graft and cyclosporine
plus methotrexate (MTX) as GVHD prophylaxis [26].
Eleven patients developed GVHD after transplant
(aGVHD grade I in 9, aGVHD grade II in 1, and
limited cGVHD in 5), although none required sys-
temic immunosuppression at the time of the first
DLI. Written informed consent was obtained before
DLI. The protocol and consent form were approved
by the Institutional Research Ethics Committee.
Assessment of Chimerism and Disease Status
Lineage-specific chimerism of peripheral blood
lymphocytes (B and T lineages) and myeloid lineage
cells was performed by analysis of informativemini-sat-
ellite short tandemrepeat (STR) loci using apolymerase
chain reaction (PCR)-based assay (n5 22), as described
elsewhere [20], or by dual-color chromosome X-Y in-
terphase fluorescent in situ hybridization (FISH) (n 5
6). Complete donor chimerism was defined by lack of
detection of a previously determined recipient-specific
peak on STR PCR in all hematopoietic lineages.
MC was defined by detection of recipient-specific
peaks (at any level) in 1 ormore cell lineages, in addition
to peaks derived from donor cells. Of the patients
treated for disease progression, 10 had both clinical
and radiologic evidence of relapse, 6 had only radio-
logic evidence of progression (computed tomography
[CT] scan in 2 and positron emission tomography
[PET] scanning in 4), and 1 patient had progressive dis-
ease diagnosed after a BM biopsy; histological
Table 1. Patient characteristics
Characteristic
Number 28
Median age at transplantation, years (range) 45 (30-64)
Sex M, 21; F, 7
Transplant conditioning and source
T-replete sibling 2
T-deplete reduced-intensity sibling 22
T-deplete reduced-intensity unrelated donor 4
Disease
Low grade NHL (FL, 14; CLL, 6; MCL, 3) 23
Transformed low grade NHL (tFL, 5) 5
GVHD before DLI
T-replete sibling 1
T-deplete reduced-intensity sibling 6
T-deplete reduced-intensity unrelated donor 1
Indication for DLI
Disease progression 1/2 MC 17
MC 11
FL indicates follicular lymphoma; CLL, chronic lymphocytic leuke-
mia; MCL, mantle cell lymphoma; tFL, transformed follicular
lymphoma.
Of the patients treated with RIT from unrelated donors, 3 received
fully HLA-matched stem cells and 1 received cells mismatched at
a single HLA allele.
52 A. J. C. Bloor et al.confirmation of disease relapse was obtained in 8 pa-
tients before DLI. Disease response was assessed on
the basis of clinical, radiologic (CT), and pathological
(BM) criteria according to the site of relapse and graded
according to standard disease-specific criteria, [27,28]
at 2-3months after eachDLI and then 6-12months af-
ter remission was achieved. PET scanning (where per-
formed) was undertaken at 3, 6, 9, 15, and 24 months
posttransplantation.
DLI Administration and Additional Treatments
In the absence of GVHD, escalating doses of
CD31 cells were administered at 3-month intervals
(1 106/kg, 3  106/kg, 1  107/kg, 3  107/kg, and
1 108/kg) in patients with persistent MC or no evi-
dence of disease response. Immunosuppression had
been discontinued in all patients before the first lym-
phocyte infusion. Twenty-three patients received an
initial dose of 1 106/kg at a median of 273 days post-
transplantation (range, 181-728 days); 5 patients with
progressive disease were treated with using a higher
initial dose. Four patients received 1  107/kg cells at
a median of 1064 days posttransplantation (range,
215-2674 days), and 1 patient received 6 107/kg cells.
Seventeen patients received DLI for disease progres-
sion, classified as relapsed disease (previous complete
remission [CR]) or progressive disease (previous partial
remission [PR]). Patients were considered evaluable for
follow-up if more than 100 days had elapsed since their
last DLI or if they had evidence of GVHD, disease re-
sponse, or disease progression before this time.GVHD
was graded according to standard criteria [29].
Patients with rapidly progressive or bulky disease
(. 5 cm diameter) were also treated with 3 or 4 weekly
infusions of rituximab (375 mg/m2) before or shortly
after DLI. Those who failed to respond to DLI were
eligible for treatment with salvage chemoradiotherapy.
Statistical Methods
Fisher’s exact test was used for analysis of 2  2 ta-
bles of cross-categorized frequency data. Survival anal-
ysis (Kaplan-Meier method) and cumulative incidence
analysis (using death as a competing risk) were per-
formed using the survival/reliability module of the
NCSS software package (NCSS, Kaysville, UT).
RESULTS
Disease Response
A total of 68 doses of DLI were administered, with
a median of 2 infusions per patient (range, 1-5). Seven-
teen patients were treated for disease progression (re-
lapse in 8 and progressive disease in 9; Table 2); 14
of these patients also had MC. Three patients had
nodal relapse in the context of peripheral blood full do-
nor chimerism, reflecting the relative insensitivity of
peripheral blood STR analysis as a marker of diseaseprogression elsewhere. One patient died before the re-
sponse to DLI could be assessed (patient 6; Table 2),
and 3 patients were refractory to treatment (patients
1, 3, and 10; Table 2).
Thirteen patients demonstrated disease response
to donor lymphocytes (Table 2), with a cumulative re-
sponse rate of 76.4% (Figure 1A; 95% confidence in-
terval [CI] 5 55.8%-99.5%). The median time to
response was 12 months. All 13 responding patients
achieved CR; in 9 of these patients, this is ongoing,
with a median duration of 967 days from last DLI
(range, 402-1769 days). Four patients demonstrated
disease progression after attaining an initial CR (pa-
tients 7, 8, 18, and 23; Table 2), although all responded
to additional lymphocyte infusions (CR in patients 7, 8,
and 23; patient 18 is currently receiving further escalat-
ing DLI). Of the 17 patients treated for disease pro-
gression, the projected 5-year overall survival (OS)
and progression-free survival (PFS) after the last treat-
ment with DLI are 87.8% (95% CI 5 72.0%-100%)
and 76.2% (95%CI 5 55.5%-96.6%), respectively
(Figure 2). PFS includes all patients in a stable remis-
sion at the time the data were evaluated.
Disease Response with Additional Treatment
before DLI
Of the patients treated for disease progression, 8
received additional treatment before or shortly after
DLI. Five patients were treated with rituximab in com-
bination with DLI (patients 14, 15, 18, 19, and 22; Ta-
ble 2). One patient is currently undergoing continued
treatment, and 4 patients have evaluable follow-up. Of
the 4 evaluable patients, all achievedCR after combina-
tion treatment using rituximab andDLI, with a median
remission duration of 776 days (range, 412-1357 days)
from their last DLI. One patient received radiotherapy
to a single lymphnodefield (patient 14;Table2), but ex-
hibited evidence of disease response outside the radia-
tion field indicating a response to DLI. Two patients
received combination chemoradiotherapy after failing
to respond to DLI (patients 1 and 10; Table 2).
Chimerism Response
A total of 25 patients received DLI for persistent
MC. Eleven had MC alone, and 14 also had progres-
sive disease (Tables 2 and 3); 2 patients died before
their response to DLI could be assessed (patients 3
and 20; Table 2 and 3). The cumulative response to
DLI for MC was 92.0% (95% CI 5 82%-100%;
Figure 1A). All of the responding patients converted
to stable full donor chimerism, and the median time
to response was 6.7 months.
GVHD
Three patients died before they could be assessed for
the development of GVHD, leaving 25 evaluable for
follow-up. Fifteen of these 25 developed GVHD (all
Table 2.
Number
Current status
GVHD Disease Chimerism
1 Acute grade I CR* FD
5 Extensive chronic CR FD
6 NE Dead (infection) -
7 Acute grade I CR FD
9 - CR FD
10 Acute grade I PR* FD
14 Extensive chronic CR FD
15 Extensive chronic CR FD
21 Extensive chronic CR FD
22 - CR FD
23 Acute grade I /
limited chronic
CR FD
28 - CR MC*
3 NE Dead (disease) -
8 - CR FD
13 - CR FD
18 Extensive chronic R* FD
19 Acute grade II /
extensive chronic
CR FD
Chemo i elated donor; R, relapse; FD, full donor; PD, progressive
disea , mantle cell lymphoma; tFL, transformed follicular lym-
phom
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Diagnosis
Transplant
Type
Treatment
before DLI
Maximum dose
DLI  106/kg
Disease status
at first DLI
Chimerism at
first DLI (method)
Best response
Disease Chimerism
CLL Sibling Chemo 10 PD MC (all) NR FD
FL RI mMUD - 10 R MC (FISH) CR FD
CLL RI MUD - 3 PD FD NE -
CLL RI sibling - 100 PD MC (T) CR FD
FL RI sibling - 30 PD MC (T) CR FD
MCL RI sibling Chemo, DXT 100 R FD NR -
FL RI sibling Rituximab, DXT 100 PD MC (all) CR FD
FL RI sibling Rituximab 60 PD MC (all) CR FD
FL RI sibling - 1 PD MC (T) CR FD
FL RI sibling Rituximab 10 PD MC (T) CR FD
MCL RI sibling - 100 R MC (T) CR FD
MCL RI MUD - 3 R FD CR -
-
tFL RI sibling - 60 PD MC (FISH) NR NE
tFL RI sibling - 100 R MC (B) CR FD
tFL RI sibling - 3 PD MC (all) CR FD
tFL RI sibling Rituximab 100 R MC (FISH) CR FD
tFL RI sibling Rituximab 30 R MC (T) CR FD
ndicates combination chemotherapy; PD, progressive disease; NR, no response; FD, full donor chimerism; mMUD, (mis)matched unr
se; NE, not evaluable; DXT, radiotherapy; PR, partial remission; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia; MCL
a.
hod used for chimerism analysis is indicated in brackets for patients withMC. All, T, B, andM refer toMC in all lineages, T lymphocytes,
analysis.
s patients undergoing continued donor lymphocyte dose escalation treatment.
54 A. J. C. Bloor et al.grades), 8ofwhomrequiredsystemic immunosuppression
(Tables 2 and 3). The cumulative incidence of aGVHD
grade II-IV was 14.7% (95% CI 5 5.9%-36.4%), and
that of extensive cGVHD was 31.4% (95% CI 5
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Figure 1. Cumulative response to DLI and incidence of GVHD. A,
Time taken to maximal response (CR or full donor chimerism) after
DLI administered for progressive disease (solid line) or MC (dashed
line). B, Cumulative incidence of extensive chronic (solid line) and
acute grade II-IV GVHD. The numbers below the figures indicate
the number of patients at risk at each time point.17.4%-56.4%) (Figure 1B). One patient developed
acute grade III hepatic aGVHD (patient 24; Table 3),
although he responded to treatment with immuno-
suppression.
A total of 63 doses of DLI were administered with
evaluable follow-up for GVHD; 50 were given in the
presence of MC, and 13 were given in the presence
of full donor chimerism (Figure 3). No difference in
the incidence of GVHD (aGVHD grade II-IV or ex-
tensive cGVHD) was seen between the 2 groups (8
of 50 mixed chimeras vs 3 of 13 full donor chimeras;
P 5 .68).
Figure 4 shows the occurrence of GVHD by dose
and timing of DLI. There was a possible excess of cases
ofGVHD (aGVHDgrade II-IV or extensive cGVHD)
after administration of DLI less than 1 year after trans-
plantation compared with doses given after this time:
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Figure 2. Survival after DLI in patients treated for relapsed/progres-
sive disease; overall (- - - -) and progression-free (——) survival after
the most recent DLI given for disease progression. Progression-free
survival includes all patients in stable CR at the time the data were
evaluated. This figure should be interpreted together with
Figure 3, which indicates the timing and dose of DLI in individual
patients.Table 3. Response to treatment in patients treated for MC alone
Number Diagnosis
Transplant
type
Maximum DLI
dose  106/kg
Chimerism
method
Best
response GVHD Current status
2 FL RI sibling 30 FISH, STR (T) FD - FD
4 FL RI sibling 30 FISH, STR (all) FD - FD
11 FL Sibling 100 FISH FD - FD
12 CLL RI sibling 1 STR (T) FD - FD
16 FL RI sibling 1 STR (M, T) FD Limited chronic FD
17 FL RI sibling 1 STR (T) FD - FD
20 FL RI sibling 1 STR (all) NE NE Dead (infection)
24 CLL RI sibling 1 STR (T) FD Acute grade III/
extensive chronic
FD
25 FL RI MUD 1 STR (T) FD - FD
26 FL RI sibling 1 STR (T) FD Acute grade II/extensive
chronic
FD
27 CLL RI sibling 1 STR (T) FD Acute grade II Dead (infection)
FD, indicates full donor chimerism; NE, not evaluable; DXT, radiotherapy; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia.
The method used for chimerism analysis is indicated in brackets for patients with MC. All, T, B, and M refer to MC in all lineages, T lympho-
cytes, B lymphocytes, and myeloid cells, respectively, using STR-PCR analysis.
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Figure 3.Timing of DLI and response to treatment by patient. The horizontal bars represent the time elapsed since trans-
plantation for each patient, colored to indicate the response to DLI by indication (MC or disease progression). Abbrevia-
tions are explained in Table 2.6 of 20 doses (\1 year) versus 5 of 43 doses (. 1 year).
However, the variation between both the number of
doses administered to individual patients and end-
points to continued dose escalation (GVHD, response,
or death) makes interpretation of the significance of
this finding uncertain.
Fifteen patients treated for disease progression
who responded to DLI were evaluable for both re-
sponse andGVHD.Of these, 7 responded without sig-
nificant GVHD (none in 5 and cutaneous grade I
aGVHD in 2). Two patients developed grade I skin
aGVHD with no significant disease response (patients
1 and 10; Table 2).
DISCUSSION
The advent of RIT protocols over the last decade
has significantly expanded the age range over which al-logeneic SCT may be applied, although the associated
procedure related morbidity and mortality, particu-
larly fromGVHD, remains significant. Most of the pa-
tients in the present study were treated with RIT and
in vivo TCD using Campath-1H. As we have reported
previously this is effective in treating patients with
NHL and results in a low incidence of GVHD, al-
though with a significant rate of disease progression
and residual recipient chimerism after transplantation
[12]. The results of this study demonstrate a significant
response to DLI for patients treated for indolent lym-
phomas with disease progression post-SCT, resulting
in a cumulative CR rate of . 75%. In most of those
treated, the remission was durable, with a median du-
ration of almost 3 years, moreover, each of the 4 pa-
tients who subsequently relapsed attained a further
remission with repeat lymphocyte infusions. These
data add to the emerging body of evidence supporting
56 A. J. C. Bloor et al.the use of DLI to treat indolent lymphoid malignan-
cies after allogeneic SCT [7,8].
A number of patients in this study receivedDLI for
disease progression diagnosed using CL-PET scan-
ing, based on the results of a previously published pilot
study describing the utility of this imaging modality to
guide the use of DLI after allogeneic SCT [30]. One
potential drawback of this approach is a lack of histo-
logical confirmation of relapse. But this may not be re-
quired in patients with a pattern of fluorodeoxyglucose
avidity that is highly suspicious for lymphoma relapse
[30], although we would recommend that biopsy be
done, if possible, in all patients with lesions at unex-
pected sites or if the clinical context suggests an alter-
native explanation (particularly infection). A biopsy is
also recommended in patients with previous high-
grade transformation given the uncertainty of the effi-
cacy of DLI for the treatment of relapsed high-grade
disease [9,12,13]. In this series, 4 of the 5 patients
with previously transformed disease responded to
DLI. These data suggest that DLI may be effective
for treating patients with previous high-grade trans-
formation, although interpretation of the significance
of these results is hampered by the lack of confirmation
of disease histology (high grade vs low grade) before
DLI in 3 of these 5 cases.
Determining the response to DLI may be more
difficult in the 8 patients treated with radiotherapy or
chemotherapy shortly before or after DLI. One of
these patients received local radiotherapy for an appar-
ently localized relapse but subsequently developed
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Figure 4. Relationship between DLI dose and incidence of GVHD.
Each circle represents the administration of a single dose of donor
lymphocytes. Black circles indicate the occurrence of acute grade
II-IV or extensive chronic GVHD; open circles indicate that
GVHD did not occur. Five doses of donor lymphocytes were not
evaluable for GVHD (not shown).more widespread disease progression and responded
to treatment with DLI outside of the radiation field,
indicating a response to donor lymphocytes. Two
other patients received chemoradiotherapy after hav-
ing failed to respond to donor lymphocytes and were
clearly refractory to DLI. Five patients with rapidly
progressive or bulky disease received 3 or 4 weekly in-
fusions of rituximab shortly before DLI. Of the 4 pa-
tients with evaluable follow-up, all achieved
a durable CR of . 2 years (median, 776 days). These
data compare favorably with previous studies using ri-
tuximab monotherapy for relapsed or refractory lym-
phoma that typically reported CR rates of \ 10%
and a median time to progression of 6-12 months
[31-33]. The results obtained in this study suggest
that the DLI may have resulted in a response (both du-
ration and quality) beyond what would be expected
when using rituximab as a single agent, and that in-
cluding these patients in the response analysis is valid.
The balance between donor and recipient hemo-
poiesis is associated with several determinants of trans-
plantation outcome. Persistent MC after allogeneic
SCT is amarker of bidirectional immune tolerance, al-
though whether or not this translates into an increased
risk of disease relapse is uncertain, and the use of DLI
in this context is controversial. Stable recipient hemo-
poiesis may persist after myeloablative conditioning,
and although some reports have suggested this may
be associated with an increased relapse rate [34,35],
other series have not confirmed this finding [36,37].
There is emerging evidence indicating that after
RIT, persistent recipient hemopoiesis correlates with
an increased risk of disease progression [38,39]. Given
the increased incidence of MC associated with TCD,
these data suggest that after alemtuzumab-based con-
ditioning, patients with persistent recipient hemato-
poiesis may not achieve long-term disease control
without DLI to achieve full donor chimerism. But
there is little consensus concerning what degree of re-
cipient hematopoiesis is significant, and levels of MC
as low as 3% have been shown to be associated with
an increased rate of disease progression [38]. However,
despite the fact that STR-PCR chimerism analysis is
sufficiently sensitive to reliably detect recipient peaks
assays of 1-5%, the quantitative accuracy of the assay
becomes less reliable at levels\5% [40]. The patients
in this series all had low levels of stable MC (rather
than more overt graft failure) that was typically below
the level of reliable quantification, and thus the detec-
tion of any level of recipient hematopoiesis was consid-
ered significant.
Chimerism status also may influence the response
to DLI and the occurrence of GVHD. In mouse
models, GVT effects are dependent in part on the
presence of host antigen-presenting cells, with
a greater GVT effect in mixed chimeras after DLI
[41], although the relevance of this observation in
Donor Lymphocytes for Non-Hodgkin Lymphoma 57human transplant recipients is uncertain. In this study,
most of the DLIs administered for disease progression
were given in the context ofMC (expected given theT-
cell deplete strategy used in most patients); however,
the response rate in full donor chimeras was not signif-
icantly different. The relationship between chimerism
status and the development of GVHD is inconsistent.
Although donor T cell chimerism soon after trans-
plantation has been associated with the development
of aGVHD [42-44], most cases of aGVHD develop
in mixed chimeras [42,45]. Chimerism status at the
time of DLI does not appear to correlate with the de-
velopment of GVHD [13,25], and consistent with this,
the incidence of GVHD in this study observed in
mixed versus full donor chimeras, was not significantly
different.
Themajor toxicity observed in this study after DLI
was GVHD, with a similar incidence to that described
in previous studies describing the use of DLI for
a range of hematologic malignancies [8,13]. However,
in contrast to those previous reports, in which disease
response was strongly correlated with the occurrence
of GVHD, almost half of the patients achieving disease
remission did so without developing significant
GVHD. The incidence of GVHD after DLI is some-
what unpredictably related to the dose infused and the
interval after transplantation and therefore the initial
dose of DLI was deferred until 6 months posttrans-
plantation [25]. In this study, there was a trend toward
increased incidence of GVHD in patients treated with
DLI less than a year after transplantation, with 5
patients requiring treatment with systemic after the
lowest dose of DLI (1  106/kg) at 6-12 months
posttransplantation. Two of the 5 received DLI for
disease progression, and the other 3 received it for
MC. Given the uncertainties regarding the signifi-
cance of MC after RIT, it is unclear whether DLI for
this indication should be delayed longer than 6months
beyond transplantation or if lower doses should be
considered in this context.
The results of this study demonstrate that DLI is
an effective and, in some patients, nontoxic interven-
tion for the treatment of relapsed indolent lymphopro-
liferative disorders post–allogeneic SCT. The data
support the existence of a meaningful graft-versus-
lymphoma effect, and although the response to DLI
is often associated with significant GVHD, in this
study a significant number of patients responded
with no graft-versus-host effect, suggesting that
GVT and GVHD in lymphoma may be separable.
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